ADC Therapeutics SA
ADCT
$3.10
-$0.01-0.32%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.21% | 27.59% | 0.71% | 27.40% | -9.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.21% | 27.59% | 0.71% | 27.40% | -9.71% |
| Cost of Revenue | -31.31% | -17.89% | -11.98% | 404.66% | -96.25% |
| Gross Profit | 11.18% | 34.93% | 13.94% | 17.65% | 222.76% |
| SG&A Expenses | -9.41% | -12.44% | -17.24% | -11.47% | -20.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.41% | -0.33% | -13.07% | 6.69% | -21.18% |
| Operating Income | -6.94% | 15.32% | 18.87% | 1.62% | 26.75% |
| Income Before Tax | -52.55% | 17.24% | 25.83% | 6.26% | 32.03% |
| Income Tax Expenses | 435.90% | 1.23% | -100.74% | 205.88% | 105.20% |
| Earnings from Continuing Operations | -55.01% | 17.17% | 63.86% | 5.90% | 25.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -55.01% | 17.17% | 63.86% | 5.90% | 25.30% |
| EBIT | -6.94% | 15.32% | 18.87% | 1.62% | 26.75% |
| EBITDA | -6.89% | 15.50% | 19.04% | 1.69% | 27.07% |
| EPS Basic | -30.40% | 36.22% | 71.79% | 26.14% | 36.40% |
| Normalized Basic EPS | 2.02% | 36.26% | 42.09% | 26.45% | 42.12% |
| EPS Diluted | -30.40% | 36.22% | 71.79% | 26.14% | 36.40% |
| Normalized Diluted EPS | 2.02% | 36.26% | 42.09% | 26.45% | 42.12% |
| Average Basic Shares Outstanding | 18.87% | 29.86% | 28.08% | 27.44% | 17.45% |
| Average Diluted Shares Outstanding | 18.87% | 29.86% | 28.08% | 27.44% | 17.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |